@article {WADA5951, author = {KENTARO WADA and NORIKO KISHI and NAOYUKI KANAYAMA and TAKERO HIRATA and MASAHIRO MORIMOTO and KOJI KONISHI and FUMIO IMAMURA and TERUKI TESHIMA and KAZUHIKO OGAWA}, title = {Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer}, volume = {38}, number = {10}, pages = {5951--5958}, year = {2018}, doi = {10.21873/anticanres.12941}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To identify clinical benefits of dose escalation in accelerated hyperfractionated radiotherapy (AH-RT) for stage III non-small-cell lung cancer (NSCLC) using propensity score-matched (PSM) analysis. Materials and Methods: Our study retrospectively examined 294 patients undergoing definitive radiotherapy [131 patients, conventional once-daily radiotherapy (OD-RT); and 163, AH-RT] who were followed-up for a median of 40.4 months. The impact of overall survival (OS), progression-free survival (PFS), and locoregional control (LRC) was investigated. Results: Pre-PSM, the median OS, PFS, and LRC durations were 23.1 vs. 39.9 (p=0.03), 8.9 vs. 13.5 (p\<0.01), and 12.9 vs. 50.3 (p\<0.01) months in the OD-RT and AH-RT groups, respectively. After-PSM (two matched groups of 144 patients), AH-RT was associated with better LRC [adjusted hazard ratio (aHR)=0.59, 95\% confidence interval (CI)=0.33-0.99, p=0.04] and marginally better PFS (aHR=0.65, 95\% CI=0.41-1.03; p=0.06), but not OS (aHR=0.75, 95\% CI=0.46-1.24; p=0.26). Conclusion: After PSM analysis, dose escalation using AH-RT improved LRC and PFS in patients with locally advanced NSCLC. AH-RT can be a promising option for patients with advanced NSCLC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/10/5951}, eprint = {https://ar.iiarjournals.org/content/38/10/5951.full.pdf}, journal = {Anticancer Research} }